Introduction
The immunosuppressive agents sirolimus, everolimus, and temsirolimus are known as proliferation signal inhibitors (PSIs). After binding to FKBP12, they inhibit the serine-threonine kinase mTOR in the multimeric protein complex mTORC1 (1) . Upon activation, this complex promotes proliferation of T and B lymphoctes, as well as many other cell types, including vascular smooth muscle, endotheial, and epithelial cells.
Sirolimus was initially approved as an immunosuppressant for use in transplantation in
1999, and the PSIs are now also being used to treat metastatic cancer, hamartomatous diseases, polycystic kidney disease (2) , and to prevent restenosis of coronary artery stents.
Unfortunately, the PSIs have a high side effect profile, including bone marrow suppression, hyperlipidemia, acne, edema, aphthous ulcers, and proteinuria (3) . A noninfectious pneumonitis was initially reported in solid organ transplant patients (4) (5) (6) (7) (8) , but appears to also occur quite commonly with oncologic use. We present a case of a deceased donor renal transplant patient who was maintained on sirolimus for over 6 years. He presented with fever, dyspnea, and interstitial pulmonary infiltrates. After nearly 2 weeks of no improvement, intravenous pentamidine was initiated. Clinical deterioration followed resulting in intubation. Open lung biopsy revealed changes typical of sirolimus toxicity, but also changes that we ascribe to concurrent pentamidine toxicity.
Case report
A 61 year-old male with a history of hepatitis C, hypertension, ESRD, and 6 years status post deceased donor renal transplantion initially presented to an outside hospital in August of 2010 with shortness of breath, lightheadedness, and pleuritic chest pain. On presentation he was afebrile with normal vital signs. The physical exam was notable for decreased breath sounds in all lung fields without wheezes or rales. Cardiac exam was normal, including no jugular venous distension. Trace lower extremity edema was noted.
No evidence for myocardial infarction was found, and an echocardiogram demonstrated normal left ventricular systolic function. The initial chest radiograph showed no acute cardiopulmonary abnormality. The serum creatinine was 1.8mg/dL, the patient's baseline.
Immunosuppression on admission included mycophenolate mofetil 1500 mg, sirolimus 2 mg, and prednisone 5 mg daily. Other outpatient medications were atenolol, amlodipine, benazepril, minoxidil, aspirin, atorvastatin, buspirion, esomeprazole, and The patient's creatinine had increased from 1.8mg/dL on day 10 to 4.0 mg/dL by day 13.
On day 14 the patient was transferred to our hospital for further management. At this time the patient's steroids were changed to high dose methylprednisolone.
Gradually, his pulmonary status improved. He defervesced and antibiotics were discontinued. On hospital day 20, he was extubated. He remained dialysis dependent. On day 22 low dose tacrolimus was added to mycophenolate mofetil. Methylprednisolone was gradually tapered as the patient's respiratory status continued to improve.
Several days after starting tacrolimus, the patient's platelet count declined precipitously. Heparin-induced thrombocytopenia was excluded. Despite multiple antihypertensive agents, the patient's blood pressure remained elevated. On day 27 the patient became confused, reported decreased vision, and then had a generalized seizure.
Brain MRI was consistent with posterior reversible encephalopathy syndrome.
Tacrolimus was discontinued due to the high suspicion for a systemic thrombotic microangiopathy. A seven-day course of plasmapharesis was initiated. Eventually the thrombocytopenia resolved.
At day 40, he was still dialysis dependent. Biopsy demonstrated persistent acute tubular damage with mild interstitial fibrosis and tubular atrophy. On electron microscopy, evidence of glomerular thrombotic microangiopathy was now noted.
On day 45 he was discharged on home oxygen. Immunosuppression consisted of mycophenolate mofetil 1500 mg daily and a slow prednisone taper. Approximately one month after discharge, home oxygen was no longer required. A follow-up CT showed significant interval improvement in the fibrosis and multifocal pneumonia.
Approximately three months after discharge, the creatinine decreased to 2.2 mg/dL, and dialysis was discontinued.
Discussion
Our patient developed sirolimus-induced pnuemonitis after 6 years of chronic use, the longest reported duration prior to development of this adverse event. The clinical course was exacerbated following addition of pentamidine with the requirement for mechanical ventilation. Lung biopsy showed the typical findings of sirolimus-induced pulmonary toxicity. In addition, the fine vacuolizations in type 2 pneumocytes and macrophages (phospholipidosis) were attributed to pentamidine toxicity.
Sirolimus was first approved for use in renal transplantation in 1999. The early, multi-center trials establishing its efficacy failed to note non-infectious pneumonitis as a significant side effect. Sirolimus-induced pneumonitis was first reported in 2000 in renal transplant patients, and subsequently with other organ transplants, including heart, lung, liver, and islet cells (4) (5) (6) (7) (8) . In some cases, sirolimus use was de novo from the time of transplantation. More frequently it was added later in the course, usually to spare calcineurin inhibitor side effects, or for malignancy. Despite the apparent absence of cases in large randomized controlled trials, single-center series in kidney and heart transplantation noted incidences as high as 10 to 15% of patients taking sirolimus (7, 8) .
The other proliferation signal inhibitors currently in use (everolimus and temsirolimus)
have subsequently also been associated with a similar non-infectious pneumonitis (9,10).
Outside of transplantation, these PSIs have also been used in oncology to treat various metaststic cancers such as renal cell, lung, or breast, where this pulmonary side effect is found much more frequently than in transplantation. Incidence rates as high as 25-40%
have been reported, although many of these cases are asymptomatic.
Regardless of the setting or particular PSI, the clinical picture is generally similar.
Symptoms include dyspnea, cough, fever, malaise, weight loss, and occasionally hemoptysis (4-8,10). Most cases occur within a few months of initiation, the longest prior reported case with sirolimus being 51 months (7). Bronchial alveolar lavage (BAL) typically reveals evidence of lymphocytic or occasionally eosinophilic alveolitis (4, 7, 8) .
Some cases initially had neutrophilic predominance suggesting infection, but on repeat BAL, lymphocytes predominated (7). Pulmonary hemorrhage occurs in a minority of cases (4, 6, 7, 8 inhibition and pulmonary toxicity, if it exists, remains to be determined.
Direct toxicity is possible based on high doses and high trough levels in many reports (4) . Some patients respond to dose reduction, a situation that allows for continued administration of the drug (4, 8) , although relapses have been reported (7, 8) . The high doses used in oncology with correspondingly very high incidences of pneumonitis support direct toxicity. In some cases, however, levels and doses were within the ranges currently recommended (6) . This suggests alternative mechanisms, at least for some patients. One hypothesis proposes exposure of cryptic pulmonary antigens by sirolimus pulmonary toxicity, which then results in initiation of a cell-mediated reaction (4). The lymphocytic predominance in most cases, especially with CD4 cells (4), supports this concept, although others have found a normal CD4:CD8 ratio (8) . It is also possible that sirolimus acts as an immunogenic hapten by binding to proteins, possibly initiating delayed type hypersensitivity (6) . The presence of eosinophils and mast cells in BAL fluid is further evidence for an allergic mechanism (4,7).
As noted, the incidences when all three PSIs are used for metastatic cancer are much higher than occurs in transplantation (10) . There are several reasons why this may be true. Cancer patients are more closely watched from the pulmonary standpoint with frequent thoracic imaging. This may allow for greater detection of asymptomatic cases.
Use of much higher doses without therapeutic drug monitoring is typical with oncologic use. For example, everolimus has been dosed at 10 mg/day, 3-5 times the typical daily dose used in transplantation. Steroids may be protective and are not usually coadministered in these patients. Finally, cancer patients are also more likely to have concurrent exposure to other potential pulmonary toxic drugs.
The clinical course of most cases of PSI pulmonary toxicity is generally rapid improvement upon cessation of the drug. Simple dose reduction may or may not be effective. Some cases have been treated with high dose steroids, but not in any controlled fashion (5, 7, 8) . In general, steroids appear to have a beneficial effect. Most patients have nearly complete recovery, but several fatalities have occurred in heart transplant patients (8) . Occasional cases have had pulmonary fibrosis detected later (5, 6) .
Surprisingly, cases are reported of patients with improved symptoms upon conversion from one PSI to another (12) .
Pentamidine also has a high side effect profile when given intravenously for treating PCP. Most notable are nephrotoxicity, hyperkalemia, dysglycemia,, and hepatotoxicity (13) . Pulmonary toxicity has not been mentioned in this context, but the concurrent infection could obscure any direct toxicity. In vitro studies show significant uptake of pentamidine and metabolites by type 2 alveolar epithelial cells and macrophages with evidence of direct toxicity (14) . Aerosolized pentamidine (AP) given to experimental animals (dogs and rats) produced both acute (alveolitis) and chronic (fibrosis) pulmonary toxicity, but at doses up to 5 times that given to patients (15) . In the clinical setting, AP shows low systemic absorption and little proclivity for either systemic or pulmonary toxicity (16) . One long term study (> 5yrs) of AP for prophylaxis in HIV patients showed only a slight reduction in flow rates, probably at the level of small airways. This effect was seen only in smokers (16) .
As a cationic amphiphilic drug (CAD), pentamidine is known to produce druginduced phospholipidosis (DIPL) (17, 18) , characterized by lysosomal acuumulation of phospholipids in the form of myeloid bodies (19) . Our patient had numerous vacuoles by light microscopy in type 2 pneumocyes and macrophages that likely represent myeloid bodies. It has been postulated that this lysosomal phospholipid accumulation results in lysosomal dysfunction with increasing autophagy, an alternative form of programmed cell death (19) . Activation of the mTORC1 complex is known to reduce autophagy (1), and hence, by inhibiting this complex, PSIs may likewise increase it. This may explain the synergistic pulmonary toxicity between a CAD like pentamidine and sirolimus seen in this case.
Our patient had a typical presentation of sirolimus-induced pulmonary toxicity, with the exception of its late onset (> 6 yrs). In addition, there was marked and rapid clinical deterioration following initiation of i.v. pentamidine. Biopsy showed direct evidence of sirolimus toxicity as well as evidence of injury to type 2 pneumocytes and macrophages indicating a synergistic pentamidine effect.
In any patient with suspected PSI-induced pneumonitis, PCP will also be a diagnostic consideration. If treatment for PCP is required, trimethoprim/sulfamethoxazole would be first choice. If not possible, we would caution against i.v. pentamidine for fear of synergistic toxicity. Furthermore, data indicate clindamycin-primaquine is more effective than pentamidine as second line therapy (20) , without this potential pulmonary risk. Whether these same concerns apply to other more commonly used medications associated with DIPL (eg amiodarone, aminoglycosides, etc) is currently unknown. 
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